But she agreed that the new French study "moves the field forward" by highlighting the apparent "dramatic improvement in survival" among elderly afforded dual-chemo treatment.
"This strongly supports doublet chemotherapy in carefully selected older individuals with NSCLC," Reckamp said. However, "the results must be balanced by a look at the increased toxicities and deaths in the combination arm. We are still in need of addition studies that evaluate older individuals with NSCLC and perform an assessment so that we might predict those who may have greater benefit or who might be at greater risk for toxicity."
For more on non-small cell lung cancer, visit the American Cancer Society.
Copyright © 2011 HealthDay. All rights reserved.